Skip to Main Content

Author Details

Robert Brown
Ovarian Cancer Action Research Centre, Imperial College London
2002
130
52
PMIDPaper TitleJournal TitlePublished Year
35326684Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?Cancers (Basel)2022
35717027Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.J Immunother Cancer2022
36694700Refractory Hydroa Vacciniforme-like Lymphoma: Biological Insights from Morphoproteomic Analysis.Int J Hematol Oncol Stem Cell Res2022
35131874Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.Mol Cancer Ther2022
33462368Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.Mod Pathol2021
33709473Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.EMBO Mol Med2021
34090482Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.Clin Epigenetics2021
33436485Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.J Immunother Cancer2021
32402285HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.Cell Rep2020
35021808Glycosylated Nanoparticles Derived from RAFT Polymerization for Effective Drug Delivery to Macrophages.ACS Appl Bio Mater2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
31092590International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis.Gut2019
29339543Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.Cancer Res2018
28176650Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?Curr Cancer Drug Targets2018
29670294The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS).Br J Cancer2018
29724815Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.Mol Cancer Res2018
29713086Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med2018
27663594Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.Clin Cancer Res2017
28109405Challenges and methodology in the incorporation of biomarkers in cancer clinical trials.Crit Rev Oncol Hematol2017
28350786Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.Br J Cancer2017
26194361Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.Pharmacogenomics J2016
27976698Epithelial ovarian carcinoma diagnosis by desorption electrospray ionization mass spectrometry imaging.Sci Rep2016
26711112Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.Nat Genet2016
26763252Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.Clin Cancer Res2016
25371448Temporal stability and determinants of white blood cell DNA methylation in the breakthrough generations study.Cancer Epidemiol Biomarkers Prev2015
26300989Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells.Clin Epigenetics2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26727311DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer.Epigenetics2015
26158617Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.Ann Med2015
25927974Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.BMC Cancer2015
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
24190013Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.Hum Genet2014
25253389Poised epigenetic states and acquired drug resistance in cancer.Nat Rev Cancer2014
25270772Nrf2, the master redox switch: the Achilles' heel of ovarian cancer?Biochim Biophys Acta2014
25072260Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination.Br J Cancer2014
24740199Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.Cancer Epidemiol Biomarkers Prev2014
24764580Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.Cancer Immunol Res2014
24642620A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.Br J Cancer2014
24272484Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.Cancer Res2014
23128397Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.Oncogene2013
24099080On the histone lysine methyltransferase activity of fungal metabolite chaetocin.J Med Chem2013
24074187Developing translational research infrastructure and capabilities associated with cancer clinical trials.Expert Rev Mol Med2013
24114859Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients.Ann Oncol2013
24089088Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors.Cancer Prev Res (Phila)2013
23917080ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.Gynecol Oncol2013
23867811DNA methylation as a long-term biomarker of exposure to tobacco smoke.Epidemiology2013
23965899Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.Clin Cancer Res2013
23963862Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.Clin Cancer Res2013
23982603Review of processing and analysis methods for DNA methylation array data.Br J Cancer2013
23672312Guidelines and considerations for conducting experiments using tissue microarrays.Histopathology2013
  • 1 - 50 of 130

Recommended Authors

Christopher F Bassil
Duke University School of Medicine Durham
Career Start Year 2013
Number of shared co-authors 0
Daniel D De Carvalho
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2010
Number of shared co-authors 1
Olga Bogatyrova
German Cancer Research Center
Career Start Year 2010
Number of shared co-authors 1
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 2
Leander Van Neste
Maastricht University Medical Center
Career Start Year 2007
Number of shared co-authors 0
Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 3
David Klinkebiel
University of Nebraska Medical Center
Career Start Year 2005
Number of shared co-authors 1
No??l J-M Raynal
Sainte-Justine University Hospital Research Center
Career Start Year 2005
Number of shared co-authors 0
Anderly C Chueh
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 1
Jason S Lee
QIMR Berghofer Medical Research Institute
Career Start Year 2003
Number of shared co-authors 63
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 10
Helai P Mohammad
Collegeville
Career Start Year 2003
Number of shared co-authors 2
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Zhuo Chen
The First Hospital of Lanzhou University
Career Start Year 2002
Number of shared co-authors 1
Joyce E Ohm
Roswell Park Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Michal R Schweiger
Institute for Translational Epigenetics, University of Cologne
Career Start Year 1999
Number of shared co-authors 1
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 20
Manon van Engeland
Maastricht University Medical Center
Career Start Year 1996
Number of shared co-authors 1
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 11
Jean-Pierre J Issa
Fels Cancer Institute for Personalized Medicine, Temple University School of Medicine
Career Start Year 1993
Number of shared co-authors 9
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 74
Joseph F Costello
University of California san francisco
Career Start Year 1991
Number of shared co-authors 7
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 37
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 11
James M Ford
Stanford University
Career Start Year 1989
Number of shared co-authors 13
Kornel E Schuebel
National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health
Career Start Year 1985
Number of shared co-authors 0
William C Reinhold
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 1
Christoph Plass
German Cancer Research Center
Career Start Year 1982
Number of shared co-authors 14
Stephen B Baylin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Career Start Year 1963
Number of shared co-authors 15

Collaborators

Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 17
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 16
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 16
Brooke L Fridley
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 15
Joellen M Schildkraut
Rollins School of Public Health, Emory University
Co-authored papers 14
Andrew Berchuck
Duke School of Medicine
Co-authored papers 14
Diether Lambrechts
Co-authored papers 14
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 14
Honglin Song
University of Cambridge
Co-authored papers 13
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 13
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 13
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 13
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 13
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 13
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 13
Jennifer A Doherty
Huntsman Cancer Institute, University of Utah
Co-authored papers 12
Montserrat Garcia-Closas
National Cancer Institute
Co-authored papers 12
Celeste Leigh Pearce
University of Michigan School of Public Health ann arbor
Co-authored papers 12
Anna H Wu
University of Southern California
Co-authored papers 12
Ian G Campbell
Co-authored papers 12
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 12
Hoda Anton-Culver
University of California irvine
Co-authored papers 12
Mary Anne Rossing
Fred Hutchinson Cancer Research Center
Co-authored papers 12
Linda E Kelemen
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 11
Sharon E Johnatty
QIMR Berghofer Medical Research Institute
Co-authored papers 11
Anna DeFazio
Westmead Hospital
Co-authored papers 11
Douglas A Levine
Perlmutter Cancer Center
Co-authored papers 11
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 11
Malcolm C Pike
Memorial Sloan-Kettering Cancer Center
Co-authored papers 11
Andreas du Bois
Co-authored papers 10
Release 1.2